Trials / Terminated
TerminatedNCT05496569
TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial of TQB3616 Capsules Versus Placebo in the Treatment of Dedifferentiated Liposarcoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A clinical trial evaluating TQB3616 capsules versus placebo in the treatment of dedifferentiated liposarcoma. Divided into 2 stages, the second stage, a total of 118 subjects are planned to be enrolled.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB3616 capsule | TQB3616 capsule is a cyclin-dependent kinase 4/6 kinase inhibitor |
| DRUG | TQB3616 placebo | Placebo |
Timeline
- Start date
- 2022-08-08
- Primary completion
- 2024-06-15
- Completion
- 2025-09-28
- First posted
- 2022-08-11
- Last updated
- 2025-11-21
Locations
3 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05496569. Inclusion in this directory is not an endorsement.